Education:
- Postdoctoral Fellow in Cancer Biology & Therapeutics, National Cancer Institute, Bethesda, MD
- Ph.D. in Pharmaceutical Sciences, University of Georgia, Athens, GA
- B.S. in Pharmacy, Shanghai Medical University (now Fudan University), China
Appointment(s):
- Associate Professor of Pharmaceutics and Drug Delivery
- Research Associate Professor in the Research Institute of Pharmaceutical Sciences
Interests:
The primary research interest in Dr. Tan’s laboratory focuses on the synthesis and evaluation of novel long-circulating nanocarriers for the targeted delivery of microRNAs and small-molecule anticancer drugs to the tumor tissues. We also investigate the novel approaches to ablate hypoxic tumor cells and boost immune response against the tumor cells. My lab is also proficient in pharmacokinetic studies and data analysis.
Selected Publications:
Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia (ATL). Cancer Res 62, 1083−6, 2002.
Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, Van Meir EG. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65, 605−12, 2005.
Mun J, Jabbar AA, Devi NS, Yin S, Wang Y, Tan C, Culver D, Snyder JP, Van Meir EG, Goodman MM. Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroaryl- sulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem 55, 6738−50, 2012.
Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS One 8, e58619, 2013.
Wang Y, Fan W, Dai X, Katragadda U, Mckinley D, Teng Q, Tan C. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles. Mol Pharmaceutics 11, 1140−50, 2014.
Fan W, Wang Y, Dai X, Shi L, Mckinley D, Tan C. Reduction-responsive crosslinked micellar nanoassemblies for tumor-targeted drug delivery. Pharm Res 32, 1325−40, 2015.
Dai X, Jiang Y, Tan C. Let-7 sensitizes KRAS mutant tumor cells to chemotherapy. PLoS One 10, e0126653, 2015.
Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Del Rev 81, 184−97, 2015.
Dai X, Fan W, Wang Y, Huang L, Jiang Y, Shi L, Mckinley D, Tan W, Tan C. Combined delivery of let-7b microRNA and paclitaxel via biodegradable nanoassemblies for the treatment of KRAS mutant cancer. Mol Pharmaceutics 13, 520−33, 2016.
Dai X, Kaluz S, Jiang Y, Shi L, Mckinley D, Wang Y, Wang B, Van Meir EG, Tan C. A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis. Oncotarget 8, 99245−60, 2017.
Zhu D, Osuka S, Zhang Z, Reichert ZE, Yang L, Kanemura Y, You S, Devi NS, Bhattacharya D, Takano S, Gillespie GY, Macdonald T, Tan C, Nishikawa R, Nelson WG, Olson JJ, Van Meir EG. BAI1 suppresses medulloblastoma formation by protecting p53 from Mdm2-mediated degradation. Cancer Cell 33, 1−33, 2018.
Kumar V, Mundra V, Peng Y, Wang Y, Tan C*, Mahato RI* (co-corresponding authors). Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics 8, 4033-49, 2018.
Fitts CA, Ji N, Li Y, Tan C. Exploiting exosomes in cancer liquid biopsies and drug delivery. Advanced Healthcare Materials 8, e1801268, 2019.
